Renal-Gastrointestinal Interactions in the Regulation of Glucose Metabolism

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08897
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54040:Metabolism and endocrinology-related
• Research Institution: Kawasaki Medical School
• Principal Investigator: Shimoda Masashi 川崎医科大学, 医学部, 講師 (60388957)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: SGLT2阻害薬 / 消化管糖輸送

Outline of Final Research Achievements

SGLT2 inhibitors correct blood glucose and body weight through forced urinary glucose excretion. From the perspective of energy homeostasis, it is possible that some mechanism of energy homeostasis may be at work under chronic administration of SGLT2 inhibitors. To test the hypothesis, diabetic and normoglycemic mouse models were divided into Luseogliflozin (Luse) and Control (Cont) groups for 2 weeks. In both models, the Luse group showed increased expression of gastrointestinal glucose transporters and incretin-related genes, and increased glucose absorption and incretin secretion. The fact that the events were observed in the normoglycemic model suggests that there is an organ system interaction independent of blood glucose fluctuations, and the renal-gastrointestinal and hepatic-gastrointestinal interactions are under investigation.

Free Research Field

糖尿病

Academic Significance and Societal Importance of the Research Achievements

SGLT2阻害薬は、2型糖尿病患者のみならず1型糖尿病患者、心不全患者、慢性腎臓病患者の健康寿命およびQOLの維持に寄与できる薬剤として多くの症例で用いられている。一方で、SGLT2阻害薬が及ぼす影響について未解明な部分も残されており、本研究はエネルギー恒常性維持の観点から、SGLT2阻害薬投与時に起こる消化管糖輸送の変化を検討したものであり、基礎医学および臨床医学において示唆に富むと考えている。